Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency

Haemophilia

Volumn 14, Issue 4, 2008, Pages 775-781

  O'Connell, Niamh M ^a,d   Riddell, A F ^a   Pascoe, G ^a   Perry, D J ^a,c   Lee, C A ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Factor XI deficiency; Recombinant factor VIIa; Surgery; Thrombin generation; Thromboelastography

Indexed keywords

BLOOD CLOTTING FACTOR 9; D DIMER; HEMOGLOBIN; IRON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FATALITY; FEMALE; HEMOPHILIA B; HEMOSTASIS; HUMAN; LIVER FUNCTION TEST; MAJOR SURGERY; MALE; MINOR SURGERY; PHLEBITIS; PILOT STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; RISK FACTOR; SIDE EFFECT; SURGICAL PATIENT; THROMBOELASTOGRAPHY; THROMBOSIS; TOOTH EXTRACTION;

ADULT; AGED; BLOOD LOSS, SURGICAL; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; FACTOR XI DEFICIENCY; FEMALE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 47649083020     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01663.x     Document Type: Article

References (43)

1. Seligsohn U. Factor XI deficiency. Thromb Haemost 1993; 70: 68-71.
2. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69: 521-8.
3. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds - a clinical and laboratory study. Thromb Haemost 1995; 73: 194-202.
4. Collins PW, Goldman E, Lilley P, Pasi KJ, Lee CA. Clinical experience of factor XI deficiency: The role of fresh frozen plasma and factor XI concentrate. Haemophilia 1995; 1: 227-31.
5. Brenner B, Laor A, Lupo H, Zivelin A, Lanir N, Seligsohn U. Bleeding predictors in factor-XI-deficient patients. Blood Coagul Fibrinolysis 1997; 8: 511-5.
6. Bolton-Maggs PH. The management of factor XI deficiency. Haemophilia 1998; 4: 683-8.
7. Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis 1992; 3: 465-8.
8. Smith JK. Factor XI deficiency and its management. Haemophilia 1996; 2: 128-36.
9. Mannucci PM, Bauer KA, Santagostino E et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84: 1314-9.
10. Gitel SN, Varon D, Schulman S, Martinowitz U. Clinical experiences of a FXI concentrate; possible side-effects. Thromb Haemost 1991; 65: 1157.
11. Bolton-Maggs PH, Colvin BT, Satchi G, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748-9.
12. Briggs NJ, Harman C, Dash CH. A decade of experience with a factor XI concentrate. Haemophilia 1996; 2(Suppl.1): 13.
13. Bolton-Maggs PH, Wensley RT, Kernoff PB et al. Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost 1992; 67: 314-9.
14. Burnouf-Radosevich M, Burnouf T. A therapeutic, highly purified factor XI concentrate from human plasma. Transfusion 1992; 32: 861-7.
15. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
16. von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
17. Lisman T, Mosnier LO, Lambert T et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 175-9.
18. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9(Suppl. 1): S61-5.
19. Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: Effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-7.
20. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114: 114-20.
21. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1: 307-17.
22. Lawler P, White B, Pye S et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8: 145-8.
23. Musso R, Cultrera G, Giuffrida G, Fichera E, Di Francesco F, Salemi S. Recombinant activated factor VIIa as haemostatic agent in homozygous factor XI deficient patients. Thromb Haemost 2001; XVIII ISTH congress (abstract P1133) Available at http://www.med.unc.edu/isth (last accessed 03.03.08).
24. Billon S, Niger CL, Escoffre-Barbe M, Vicariot M, Abgrall JF. The use of recombinant factor VIIa (NovoSeven(R)) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 551-3.
25. Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000; 26: 413-9.
26. Salooja N, Perry DJ. Thromboelastography. Blood Coagul Fibrinolysis 2001; 12: 327-37.
27. Hemker HC, Beguin S. Endogenous thrombin potential. In: Jespersen J, Bertina RM, Haverkate F, eds. Laboratory Techniques in Thrombosis - A Manual. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1999: 63-78.
28. Salomon O, Zivelin A, Levnat T et al. Prevalence, causes and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101: 4783-8.
29. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114-24.
30. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis 1996; 26(Suppl. 1): 102-8.
31. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus FVIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
32. Salomon O, Steinberg DM, Dardik R et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003; 1: 658-61.
33. Brown SA. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia 2005; 11: 430-1.
34. Schulman S, Nemeth G. An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia 2006; 12: 223-7.
35. Ingerslev J, Christiansen K, Calatzis A, Holm M, Sabroe Ebbesen L. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S25-30.
36. Cid AR, Lorenzo JI, Haya S, Montoro JM, Casana P, Aznar JA. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia 2001; 7: 39-41.
37. Johannessen M, Nielsen G, Nordfang O. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S159-64.
38. He S, Blomback M, Jacobsson EG, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-9.
39. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
40. Bouma BN, Meijers JC. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol 2000; 7: 266-72.
41. Salomon O, Steinberg DM, Seligsohn U. Variable bleeding manifestations characterize different types of surgery in patients with severe FXI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12: 490-3.
42. Llewelyn CA, Hewitt PE, Knight RS et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
43. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.